4 results match your criteria: "Ruth M. Rothstein CORE Center and Stroger Hospital of Cook County[Affiliation]"
HIV integrase strand transfer inhibitors (INSTI) are considered well tolerated with few treatment-limiting adverse effects. However, emerging data from clinical trials has identified excessive weight gain possibly due to INSTI alone or with tenofovir alafenamide as a new and possible long-term complication of combination antiretroviral therapy (cART). Identifying who is at greatest risk and whether the unintended weight gain is reversible remain unanswered questions.
View Article and Find Full Text PDFHIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir.
Infect Dis Ther
September 2020
Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, USA.
A potential drug-drug interaction exists between divalent and trivalent cations (Ca, Fe, Mg, Al, Zn) and HIV-1 integrase strand transfer inhibitors (INSTIs). There are limited case reports describing the clinical significance of this potential interaction and none to our knowledge identifying zinc co-administration with INSTIs. In this report we present a patient taking bictegravir/emtricitabine/tenofovir alafenamide who became viremic after ingesting zinc and calcium supplements and later was able to obtain virologic re-suppression after discontinuing supplements.
View Article and Find Full Text PDFRandomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis.
N Engl J Med
May 2020
From the Departments of Obstetrics, Gynecology, and Reproductive Sciences (C.R.C., S.N., A.H.) and Laboratory Medicine (L.G., S. Miller), University of California, San Francisco, San Francisco, the Department of Family Medicine, University of California, San Diego, San Diego (S. Morris), and Osel, Mountain View (T.P.) - all in California; Emmes, Rockville, MD (M.R.W., J.P.); the Department of Medicine, Ruth M. Rothstein CORE Center and Stroger Hospital of Cook County Health, Rush University Medical Center, Chicago (A.L.F.); and the Division of Infectious Diseases, Department of Medicine, Washington University, St. Louis (H.R.).
Background: Bacterial vaginosis affects 15 to 50% of women of reproductive age, and recurrence is common after treatment with an antibiotic agent. The high incidence of recurrence suggests the need for new treatments to prevent recurrent bacterial vaginosis.
Methods: We conducted a randomized, double-blind, placebo-controlled, phase 2b trial to evaluate the ability of CTV-05 (Lactin-V) to prevent the recurrence of bacterial vaginosis.
A Measure to Assess HIV Treatment Readiness among Adolescents and Young Adults.
Vulnerable Child Youth Stud
April 2019
Department of Psychiatry, Ruth M. Rothstein CORE Center and Stroger Hospital of Cook County, Chicago, IL.
HIV infections among adolescents and young adults continue to grow and clinical guidelines recommend the immediate start of life-saving antiretroviral therapy (ART). Unfortunately, suboptimal medication adherence among youth is common and can lead to poorer health outcomes as well as onward transmission of HIV to sexual partners. Clinical tools to assess treatment readiness are needed and can assist with adherence intervention strategies for youth.
View Article and Find Full Text PDF